VCEL (Vericel) Preferred Dividends : $0.0 Mil (TTM As of Sep. 2024)

View and export this data going back to 1997. Start your Free Trial

What is Vericel Preferred Dividends?

Preferred dividend is a dividend that is accrued and paid on a company's preferred shares. Vericel's preferred dividends for the three months ended in Sep. 2024 was $0.0 Mil. Its preferred dividends for the trailing twelve months (TTM) ended in Sep. 2024 was $0.0 Mil.

Vericel Preferred Dividends Historical Data

The historical data trend for Vericel's Preferred Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vericel Preferred Dividends Chart

Vericel Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Preferred Dividends

Get a 7-Day Free Trial

Vericel Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Preferred Dividends	Get a 7-Day Free Trial															-	-	-	-	-

Vericel Preferred Dividends Calculation

A dividend that is accrued and paid on a company's preferred shares.

Vericel (NAS:VCEL) Preferred Dividends Explanation

In the event that a company is unable to pay all dividends, claims to preferred dividends take precedence over claims to dividends that are paid on common shares.

Preferred Dividends for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

Vericel Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vericel Corp (NAS:VCEL) » Definitions » Preferred Dividends

Comparable Companies

Traded in Other Exchanges

ATQP:Germany

Address

64 Sidney Street, Cambridge, MA, USA, 02139

Website

https://www.vcel.com

Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in various therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.

Executives

Paul K Wotton	director	C/O ANTARES PHARMA, INC., 707 EAGLEVIEW BOULEVARD, SUITE 414, EXTON PA 19341
Jonathan Mark Hopper	officer: Chief Medical Officer	64 SIDNEY STREET, CAMBRIDGE MA 02139
Zerbe Robert L Md	director
Dominick Colangelo	director, officer: President and CEO	1000 WINTER ST., SUITE 2200, WALTHAM MA 02451
Kevin F Mclaughlin	director	C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
Steven C Gilman	director	110 HARTWELL AVENUE, LEXINGTON MA 02421
Sean C. Flynn	officer: SVP, General Counsel	C/O VERICEL CORPORATION, 64 SIDNEY ST., CAMBRIDGE MA 02139
Mara Joseph Anthony Jr	officer: Chief Financial Officer	C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Jonathan Siegal	officer: Principal Accounting Officer	C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Michael Halpin	officer: Chief Operating Officer	C/O VERICEL CORPORATION, 64 SIDNEY ST., CAMBRIDGE MA 02139
Lisa Wright	director	C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Sandra Pennell	officer: VP and Corporate Controller	C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Gerard J Michel	officer: CFO & VP , Corp. Development	420 CHIPETA WAY, SALT LAKE CITY UT 84108
Daniel Orlando	officer: Chief Operating Officer	P.O. BOX 376, ANN ARBOR MI 48105
Alan L Rubino	director	PO BOX 376, LOBBY L., ANN ARBOR MI 48105